In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 141 to 150 of 303

TitleTypeExpected publication date
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]Technology appraisal guidanceTBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863Technology appraisal guidanceTBC
Linzagolix for treating symptoms of endometriosis [ID6357]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]Technology appraisal guidanceTBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]Technology appraisal guidanceTBC
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]Technology appraisal guidanceTBC
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]Technology appraisal guidance
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All